静脉靶向纳米肽CAQK在大鼠脊髓损伤中具有神经保护作用并改善运动功能
该研究使用12只雌性Sprague-Dawley大鼠建立C5右侧脊髓半挫伤模型,随机接受静脉CAQK(2.5 mg/kg)或生理盐水,伤后1小时开始每日给药共7天。采用IBB前肢恢复量表(0–9分,9分为正常功能)在8周内5个时间点评估运动功能,随后行组织学分析,并辅以体外神经保护实验。结果:CAQK组在伤后1、2、5、8周运动恢复均显著优于生理盐水组(第8周IBB 7 vs 3,p=0.01);组织学显示CAQK组星形胶质活化显著减少(GFAP:治疗组0.1±0.01 vs 未治疗组0.7±0.2,p=0.002),轴突保留增加(NFM:治疗组0.3±0.06 vs 未治疗组0.1±0.06,p=0.03);体外实验中CAQK较生理盐水显著增强神经元网络复杂性(p<0.05)。结论支持CAQK作为脊髓损伤靶向治疗候选药物的潜力。
要点
- 大鼠C5右侧脊髓半挫伤后1小时开始每日静脉给予CAQK 2.5 mg/kg共7天,第8周IBB运动评分7 vs 生理盐水组3(p=0.01)。
- CAQK组伤后1、2、5、8周运动恢复均显著优于生理盐水组。
- 组织学:CAQK组GFAP 0.1±0.01 vs 未治疗组0.7±0.2(p=0.002),星形胶质活化显著减少。
- 组织学:CAQK组NFM 0.3±0.06 vs 未治疗组0.1±0.06(p=0.03),轴突保留显著增加。
- 体外实验中CAQK较生理盐水显著增强神经元网络复杂性(p<0.05)。
适用人群与场景
- 雌性Sprague-Dawley大鼠(12只),C5右侧脊髓半挫伤模型,伤后1小时开始给药。
诊断标准与关键阈值
- 运动功能评估采用Irvine、Beatties和Bresnahan(IBB)前肢恢复量表,评分范围0–9分,9分为正常功能。
处置流程与药物剂量
- CAQK 2.5 mg/kg,静脉给药,每日一次,伤后1小时开始,连续7天(动物实验方案)。
研究设计与关键结果
- 研究类型:动物实验(大鼠脊髓损伤模型)联合体外神经保护实验;样本量12只雌性Sprague-Dawley大鼠。
- 干预与对照:随机接受静脉CAQK(2.5 mg/kg)或生理盐水,每日一次共7天,伤后1小时开始。
- 主要运动终点:第8周IBB评分CAQK组7 vs 生理盐水组3(p=0.01);伤后1、2、5、8周CAQK组运动恢复均显著优于生理盐水组。
- 组织学终点:GFAP治疗组0.1±0.01 vs 未治疗组0.7±0.2(p=0.002);NFM治疗组0.3±0.06 vs 未治疗组0.1±0.06(p=0.03)。
- 体外实验:CAQK较生理盐水显著增强神经元网络复杂性(p<0.05)。
证据类型、等级与局限
- 证据类型:动物实验(大鼠脊髓损伤模型)及体外实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论认为这些发现支持CAQK作为脊髓损伤靶向治疗候选药物的潜力。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: CAQK is a homing peptide that targets sites of central nervous system injury and has previously demonstrated functional benefits in traumatic brain injury models. We recently demonstrated its localization to spinal cord injury (SCI) after intravenous administration and hypothesized that it could enhance motor recovery after SCI.
METHODS: Twelve female Sprague-Dawley rats underwent C5 right-sided spinal cord hemicontusion. Animals were randomized to receive intravenous CAQK (2.5 mg/kg) or saline daily for 7 days, beginning 1 hour postinjury. Motor performance was assessed using the Irvine, Beatties, and Bresnahan (IBB) Forelimb Recovery Scale, a scale from 0 to 9, with 9 being normal function. IBB score was assessed at five time points over 8 weeks, followed by histological analysis. An in vitro neuroprotection assay was also conducted to evaluate the neuroprotective effects of CAQK at various doses.
RESULTS: All animals exhibited motor deficits immediately after injury. Compared with saline controls, CAQK-treated rats demonstrated significantly improved motor recovery at 1, 2, 5, and 8 weeks postinjury (week 8: IBB = 7 vs. 3; p = 0.01). Histologic analysis showed significantly reduced astroglial activation in the CAQK group (GFAP: treated = 0.1±0.01 vs. untreated = 0.7±0.2; p = 0.002) and increased axonal preservation (NFM: treated = 0.3±0.06 vs. untreated = 0.1±0.06; p = 0.03). In vitro, CAQK significantly enhanced neuronal network complexity compared with saline ( p < 0.05).
CONCLUSIONS: CAQK treatment significantly improved motor outcomes compared with saline-only treatment. Ex vivo analysis of spinal cord tissue showed enhanced tissue recovery in CAQK-treated rats. In vitro, neuroprotection was evident in cells treated with CAQK. Overall, these findings support CAQK's potential as a targeted therapeutic candidate for SCI.
参考来源
- Castillo JA, Uppuluri J, Le M, et al. The intravenous targeted nanopeptide, CAQK, is neuroprotective and improves motor function after spinal cord injury in rats. J Trauma Acute Care Surg. 2026. PMID: 42378652. doi:10.1097/TA.0000000000005054
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。